参考文献/References:
[1] Dong T,Alencherry B,Ospina S,et al. Review of mavacamten for obstructive hypertrophic cardiomyopathy and future directions[J]. Drug Des Devel Ther,2023,17,1097-1106.
[2] Semsarian C,Ingles J,Maron MS,et al. New perspectives on the prevalence of hypertrophic cardiomyopathy[J]. J Am Coll Cardiol,2015,65(12):1249-1254.
[3] 国家心血管病中心心肌病专科联盟,中国医疗保健国际交流促进会心血管病精准医学分会“中国成人肥厚型心肌病诊断与治疗指南2023”专家组. 中国成人肥厚型心肌病诊断与治疗指南2023[J]. 中国循环杂志,2023,38(1):1-33.
[4] Ommen SR,Mital S,Burke MA,et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy:Executive Summary:A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines [J]. Circulation,2020,142(25):e533-e557.
[5] Sakellaropoulos SG,Steinberg BS. Hypertrophic Cardiomyopathy:a cardiovascular challenge becoming a contemporary treatable disease[J]. Cardiol Res,2023,14(4):243-249.
[6] Nag S,Trivedi DV. To lie or not to lie:super-relaxing with myosins[J]. ELIFE,2021,10:e63703.
[7] Margara F,Psaras Y,Wang ZJ,et al. Mechanism based therapies enable personalised treatment of hypertrophic cardiomyopathy[J]. Sci Rep,2022,12(1):22501.
[8] Braunwald E,Saberi S,Abraham TP,et al. Mavacamten:a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy[J]. Eur Heart J,2023,44(44):4622-4633.
[9] Bos JM,Will ML,Gersh BJ,et al. Characterization of a phenotype-based genetic test prediction score for unrelated patients with hypertrophic cardiomyopathy[J]. Mayo Clin Proc,2014,89(6):727-737.
[10] Packard E,de Feria A,Peshin S,et al. Contemporary therapies and future directions in the management of hypertrophic cardiomyopathy[J]. Cardiol Ther,2022,11(4):491-507.
[11] Iavarone M,Monda E,Vritz O,et al. Medical treatment of patients with hypertrophic cardiomyopathy:an overview of current and emerging therapy[J]. Arch Cardiovasc Dis,2022,115(10):529-537.
[12] Aguiar T,Martins E. Mavacamten,a novel revolutionizing therapy in hypertrophic obstructive cardiomyopathy:a literature review[J]. Rev Port Cardiol,2022,41(8):693-703.
[13] Heitner SB,Jacoby D,Lester SJ,et al. Mavacamten treatment for obstructive hypertrophic cardiomyopathy:a clinical trial[J]. Ann Intern Med,2019,170(11):741-748.
[14] Spertus JA,Fine JT,Elliott P,et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM):health status analysis of a randomised,double-blind,placebo-controlled,phase 3 trial[J]. Lancet,2021,397(10293):2467-2475.
[15] Olivotto I,Oreziak A,Barriales-Villa R,et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM):a randomised,double-blind,placebo-controlled,phase 3 trial[J]. Lancet,2020,396(10253):759-769.
[16] Desai MY,Owens A,Geske JB,et al. Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy[J]. J Am Coll Cardiol,2022,80(2):95-108.
[17] Tian Z,Wang F,Jin W,et al. Study design and rationale of EXPLORER-CN:a phase III,randomised,double-blind,placebo-controlled clinical study to evaluate the efficacy and safety of mavacamten in Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy[J]. BMJ Open,2023,13(6):e071473.
[18] Tian Z,Li L,Li X,et al. Effect of mavacamten on chinese patients with symptomatic obstructive hypertrophic cardiomyopathy:the EXPLORER-CN randomized clinical trial[J]. JAMA Cardiol,2023,8(10):957-965.
[19] Memon A,Larik MO,Khan Z,et al. Efficacy and safety of mav acamten in treatment of hypertrophic cardiomyopathy:a systematic review and meta-analysis[J]. Future Sci OA,2023,9(10):FS0898.
[20] Scholtz S,Rudolph V,Reil JC. Alcohol septal ablation or mavacamten for obstructive hypertrophic cardiomyopathy[J]. J Clin Med,2023,12(20):6628.
[21] Grillo MP,Erve JCL,Dick R,et al. In vitro and in vivo pharmacokinetic characterization of mavacamten,a first-in-class small molecule allosteric modulator of beta cardiac myosin[J]. Xenobiotica,2019,49(6):718-733.
[22] Rader F,Or?ziak A,Choudhury L,et al. Mavacamten treatment for symptomatic?obstructive hypertrophic?cardiomyopathy:interim results from the MAVA-LTE study,EXPLORER-LTE?cohort[J]. JACC Heart Fail,2024,12(1):164-177.
[23] Patel RB,Shah SJ. Inclusion criteria for heart failure with preserved ejection fraction clinical trials:making the case for precision diagnosis and greater inclusivity[J]. J Card Fail,2022,28(5):732-735.
[24] Rao SJ,Forst B,Kanwal AK,et al. Cardiac myosin inhibitors for hypertrophic cardiomyopathy:shedding light on their clinical potential[J]. Expert Opin Investig Drugs,2023,32(1):1-4.
[25] Anderson RL,Trivedi DV,Sarkar SS,et al. Deciphering the super relaxed state of human β-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers[J]. Proc Natl Acad Sci U S A,2018,115(35):E8143-E8152.
[26] Zhang H,Yu C,Cheng Y,et al. Clinical trials in hypertrophic cardiomyopathy therapy:a comprehensive analysis of trials registered in Global Clinical Databases[J]. Drug Des Devel Ther,2023,17:1863-1877.
[27] Chuang C,Collibee S,Ashcraft L,et al. Discovery of aficamten (CK-274),a next-generation cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy[J]. J Med Chem,2021,64(19):14142-14152.
[28] Maron MS,Masri A,Choudhury L,et al. Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy[J]. J Am Coll Cardiol,2023,81(1):34-45.
[29] Nag S,Gollapudi SK,del Rio CL,et al. Mavacamten,a precision medicine for hypertrophic cardiomyopathy:from a motor protein to patients[J]. Sci Adv,2023,9(30):eabo7622.
[30] Ho CY,Mealiffe ME,Bach RG,et al. Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy[J]. J Am Coll Cardiol,2020,75(21):2649-2660.
相似文献/References:
[1]冯坤,刘春霞,熊峰,等.超声心动图在肥厚型心肌病诊治中的应用进展[J].心血管病学进展,2016,(4):409.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.021]
FENG Kun,LIU Chunxia,XIONG Feng,et al.Progress in Application of Echocardiography in
Diagnosis and Treatment of Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2016,(10):409.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.021]
[2]熊峰.梗阻性肥厚型心肌病治疗方法的现状与进展[J].心血管病学进展,2019,(6):889.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.013]
XIONG Feng.Current Status and Progress of Treatment of Hypertrophy Obstructive Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(10):889.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.013]
[3]黄淮滨 刘甲兴.肥厚型心肌病治疗新靶点——钙脱敏治疗[J].心血管病学进展,2019,(7):1047.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.021]
HUANG HuaibinLIU Jiaxing.A Novel Target for Therapy in Hypertrophic Cardiomyopathy: Ca2+ desensitizer[J].Advances in Cardiovascular Diseases,2019,(10):1047.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.021]
[4]马秀英 贾锋鹏.肥厚型心肌病并发心房颤动的危险因素研究进展[J].心血管病学进展,2020,(12):1243.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.005]
MA XiuyingJIA Fengpeng.Update about the Risk Factors of Hypertrophic Cardiomyopathy Complicated with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2020,(10):1243.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.005]
[5]邓清文,何森.肥厚型心肌病合并心房颤动的研究进展[J].心血管病学进展,2021,(4):27.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.010]
DENG Qingwen,HE Sen.Hypertrophic Cardiomyopathy Complicated with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(10):27.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.010]
[6]尚依一 刘罗 庞明杰 张艳.基因检测在肥厚型心肌病中的应用进展[J].心血管病学进展,2021,(6):512.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.009]
SHANG Yiyi,LIU Luo,PANG Mingjie,et al.Gene Detection for Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(10):512.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.009]
[7]王娟 杨艳敏.肥厚型心肌病发生缺血性卒中的危险因素和管理策略研究进展[J].心血管病学进展,2021,(7):582.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.002]
WANG Juan,YANG Yanmin.Risk Factors and Management Strategies of Ischemic Stroke in Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(10):582.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.002]
[8]武志刚 孙佳莉 王巍.基于心脏磁共振成像的肥厚型心肌病患者早期峰值充盈率与舒张功能相关性的研究[J].心血管病学进展,2021,(7):658.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.020]
WU Zhigang,SUN Jiali,WANG Wei.Correlation Between Early Peak Filling Rate and Diastolic Function in Patients with Hypertrophic Cardiomyopathy Based on Cardiac Magnetic Resonance Imaging[J].Advances in Cardiovascular Diseases,2021,(10):658.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.020]
[9]蓝庆肃 武锋超 马兰虎 韩冰 徐金 彭瑜 张钲.Mavacamten治疗肥厚型心肌病的研究进展[J].心血管病学进展,2021,(11):1028.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
LAN Qingsu,WU Fengchao,MA Lanhu,et al.Mavacamten in Treatment of Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(10):1028.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
[10]李传伟,罗浩,曾春雨.肥厚型心肌病室间隔消减策略的研究进展[J].心血管病学进展,2022,(1):7.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.002]
LI Chuanwei,LUO Hao,ZENG Chunyu.Septal Reduction Therapy of Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2022,(10):7.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.002]